ClinicalTrials.gg
CompletedNCT01753570Updated Jan 6, 2026Results posted

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

A Phase 3 interventional study of MP-424 and RBV(24 weeks) in Chronic Hepatitis C(CHC), sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.

Enrollment
11th of 27
74 · median 54
Started
2012
with 8 others
Phase 3
12 of 27
none open now
Registered
20th of 27
by date
Lead sponsor
9 of 27
Tanabe Pharma Corporation

Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 11th largest by enrollment, is one of 9 that started in 2012, is one of 12 in phase 3, and was the 20th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing telaprevir in Hepatitis C, Chronic as a file.
02

Study summary

This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.

03

Conditions studied

  • Chronic Hepatitis C(CHC)

Browse trials for

Keywords

  • Feron
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genotype 1 or 2, chronic , with depression(including the past)
  • Treatment-naïve(Genotype 1 only) or patient who have ever had previous IFN based treatment
  • Able and willing to follow requirements

Exclusion criteria

Exclusion Criteria:

  • Cirrhosis of the liver or hepatic failure
  • surface antigen-positive or antibodies-positive
  • History of, or concurrent hepatocellular carcinoma
  • History of, or concurrent serious depression, schizophrenia, or suicide attempt in the past
  • Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    MP-424+RBV+IFN beta, Genotype1

    Drug: MP-424 · Drug: RBV(24 weeks) · Drug: IFN beta(24 weeks)

  • Experimental
    RBV+IFN beta, Genotype1

    Drug: RBV(48 weeks) · Drug: IFN beta(48 weeks)

  • Experimental
    MP-424+RBV+IFN beta, Genotype2

    Drug: MP-424 · Drug: RBV(24 weeks) · Drug: IFN beta(24 weeks)

Interventions

06

What researchers measure

Primary outcomes

  1. Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)

    Time frame: 72 weeks(RBV+IFN beta), 48 weeks(MP-424+RBV+IFN beta)

Secondary outcomes

  1. Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)

    Time frame: 4 weeks

  2. Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)

    Time frame: 48 weeks(RBV+IFN beta), 24 weeks(MP-424+RBV+IFN beta)

  3. Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration

    Time frame: 60 weeks(RBV+IFN beta), 36 weeks(MP-424+RBV+IFN beta)

  4. Transition of Serum HCV RNA Levels

    Time frame: Baseline,Day2,Day3,1Week,2Weeks,3Weeks,4Weeks,12Weeks,End of treatment,Follow-up 12weeks,Follow-up 24weeks

  5. Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV.

    To examine the emergence of resistance-associated variants after MP-424 administration.

    Time frame: From baseline to 24 weeks after completion of drug administration

07

Results

Posted Oct 26, 2018

Participant flow

Participant flow — Overall Study
MilestoneMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Started303014
Completed282513
Not completed251
Withdrew: Adverse event101
Withdrew: Physician decision010
Withdrew: Withdrawal by subject140

Outcome measures

PrimaryUndetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
Time frame:
72 weeks(RBV+IFN beta), 48 weeks(MP-424+RBV+IFN beta)
Reported as:
Number · percentage of subjects achieving SVR
Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
percentage of subjects achieving SVRMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)63.3 (43.9 to 80.1)20.0 (7.7 to 38.6)71.4 (41.9 to 91.6)
SecondaryUndetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)
Time frame:
4 weeks
Reported as:
Number · percentage of subjects achieving RVR
Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)
percentage of subjects achieving RVRMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)70.0 (50.6 to 85.3)6.7 (0.8 to 22.1)92.9 (66.1 to 99.8)
SecondaryUndetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)
Time frame:
48 weeks(RBV+IFN beta), 24 weeks(MP-424+RBV+IFN beta)
Reported as:
Number · percentage of subjects achieving ETR
Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)
percentage of subjects achieving ETRMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)76.7 (57.7 to 90.1)30.0 (14.7 to 49.4)85.7 (57.2 to 98.2)
SecondaryUndetectable HCV RNA at 12 Weeks After Completion of Drug Administration
Time frame:
60 weeks(RBV+IFN beta), 36 weeks(MP-424+RBV+IFN beta)
Reported as:
Number · percentage of subjects achieving SVR12
Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration
percentage of subjects achieving SVR12MP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration66.7 (47.2 to 82.7)20.0 (7.7 to 38.6)71.4 (41.9 to 91.6)
SecondaryTransition of Serum HCV RNA Levels
Time frame:
Baseline,Day2,Day3,1Week,2Weeks,3Weeks,4Weeks,12Weeks,End of treatment,Follow-up 12weeks,Follow-up 24weeks
Reported as:
Median · log IU/mL
Transition of Serum HCV RNA Levels
log IU/mLMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Baseline6.73 (6.40 to 7.15)6.83 (6.55 to 7.15)6.05 (5.45 to 6.75)
Day24.15 (3.80 to 4.80)5.65 (5.20 to 6.10)3.80 (3.10 to 4.40)
Day33.35 (3.00 to 3.60)4.85 (4.40 to 5.30)2.80 (2.30 to 3.30)
1Week2.40 (1.90 to 2.80)5.30 (4.50 to 5.70)1.25 (0.50 to 2.00)
2Weeks1.30 (1.00 to 1.80)4.60 (3.70 to 5.30)0.50 (0.50 to 1.40)
3Weeks0.50 (0.50 to 1.00)3.70 (2.90 to 4.80)0.50 (0.50 to 0.50)
4Weeks0.50 (0.50 to 0.75)3.20 (2.00 to 4.20)0.50 (0.50 to 0.50)
12Weeks0.50 (0.50 to 0.50)2.75 (0.50 to 4.75)0.50 (0.50 to 0.50)
End of treatment0.50 (0.50 to 0.50)3.20 (0.50 to 5.60)0.50 (0.50 to 0.50)
Follow-up 12weeks0.50 (0.50 to 6.00)6.20 (5.00 to 6.70)0.50 (0.50 to 0.50)
Follow-up 24weeks0.50 (0.50 to 6.60)6.20 (5.40 to 6.80)0.50 (0.50 to 0.50)
SecondaryNumber of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV.

To examine the emergence of resistance-associated variants after MP-424 administration.

Time frame:
From baseline to 24 weeks after completion of drug administration
Reported as:
Number · participants
Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV.
participantsMP-424+RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
V36M10
T54A10
T54S,A156T,V36A10
T54A,R155W01
Not detected51

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MP-424+RBV+IFN Beta, Genotype1—4/30 (13.3%)30/30 (100%)
RBV+IFN Beta, Genotype1—3/30 (10%)30/30 (100%)
MP-424+RBV+IFN Beta, Genotype2—5/14 (35.7%)14/14 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/301/14
AnaemiaBlood and lymphatic system disorders0/300/301/14
CataractEye disorders0/300/301/14
Optic nerve disorderEye disorders0/300/301/14
Renal impairmentRenal and urinary disorders0/300/301/14
Blood bilirubin increasedInvestigations0/300/301/14
Foot fractureInjury, poisoning and procedural complications0/300/301/14
PneumoniaInfections and infestations1/300/300/14
Chronic sinusitisInfections and infestations0/301/300/14
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/300/300/14
Most frequent other events
Showing 10 of 119
Most frequent other events
EventMP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2
PyrexiaGeneral disorders22/3026/3014/14
AnaemiaBlood and lymphatic system disorders25/3017/3011/14
Blood uric acid increasedInvestigations13/305/3010/14
MalaiseGeneral disorders18/3014/307/14
HeadacheNervous system disorders14/3015/306/14
RashSkin and subcutaneous tissue disorders13/305/307/14
InsomniaPsychiatric disorders8/306/306/14
NasopharyngitisInfections and infestations8/3012/304/14
NauseaGastrointestinal disorders12/306/304/14
Blood creatinine increasedInvestigations12/300/305/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)MP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2Total
Mean60.5 ± 6.457.6 ± 10.555.4 ± 7.758.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)MP-424+RBV+IFN Beta, Genotype1RBV+IFN Beta, Genotype1MP-424+RBV+IFN Beta, Genotype2Total
Female2221952
Male89522
08

Study locations

1 site
  • Toranomon Hospital
    Kawasaki, Takatsu-ku 213-8587, Japan
09

References and documents

Publications

  • Kumada H, Mochida S, Nakamuta M, Suzuki F, Yagi T, Takasaki R, Okai M, Kamiya N, Okada Y, Hirota S, Orihashi M, Ochi M, Chayama K. Efficacy and safety of telaprevir with natural human interferon-beta and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res. 2018 Feb;48(2):184-192. doi: 10.1111/hepr.12914. Epub 2017 Jul 19. PubMed 28497489 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Dec 20, 2012
Start
Dec 2012
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Oct 26, 2018
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01753570
Collaborators
Toray Industries, Inc
Responsible party
Sponsor
First posted
Dec 20, 2012
Start date
Dec 2012
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Oct 26, 2018
Last update
Jan 6, 2026

Study contacts

Kazuoki Kondo, M.D.
study director · Tanabe Pharma Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Ribavirin · Interferon beta · Interferon beta-1b · Interferon beta-1a

Start the discussion